BGF World Healthscience Fund E2 EUR
LU0171309270
BGF World Healthscience Fund E2 EUR/ LU0171309270 /
NAV28.06.2024 |
Zm.+0,1600 |
Typ dystrybucji dochodów |
Kategoria |
Firma inwestycyjna |
59,8800EUR |
+0,27% |
z reinwestycją |
Akcje
Światowy
|
BlackRock (LU) ▶ |
Strategia inwestycyjna
The Fund aims to maximise the return on your investment through a combination of capital growth and income on the Fund"s assets and invest in a manner consistent with the principles of environmental, social and governance (ESG) investing. The Fund invests globally at least 70% of its total assets in the equity securities (e.g. shares) of companies the main business of which is in healthcare, pharmaceuticals, medical technology and supplies and the development of biotechnology.
The investment adviser (IA) may use financial derivative instruments (FDIs) (i.e. investments the prices of which are based on one or more underlying assets) for investment purposes in order to achieve the investment objective of the Fund, and/or to reduce risk within the Fund"s portfolio, reduce investment costs and generate additional income. The Fund may, via FDIs, generate varying amounts of market leverage (i.e. where the Fund gains market exposure in excess of the value of its assets). The Fund is actively managed, and the IA has discretion to select the Fund's investments. In doing, the IA will refer to the MSCI World Health Care Index (the "Index") when constructing the Fund"s portfolio, and also for performance comparison and risk management purposes, as further described in the prospectus. The IA is not bound by the components or weighting of the Index. and may also use its discretion to invest in securities not included in the Index. However, the sector requirements of the investment objective and policy may limit the extent to which the portfolio holdings will deviate from the Index.
Cel inwestycyjny
The Fund aims to maximise the return on your investment through a combination of capital growth and income on the Fund"s assets and invest in a manner consistent with the principles of environmental, social and governance (ESG) investing. The Fund invests globally at least 70% of its total assets in the equity securities (e.g. shares) of companies the main business of which is in healthcare, pharmaceuticals, medical technology and supplies and the development of biotechnology.
Dane podstawowe
Typ dystrybucji dochodów: |
z reinwestycją |
Kategoria funduszy: |
Akcje |
Region: |
Światowy |
Branża: |
Sector Health / Pharma |
Benchmark: |
MSCI World Health Care Index |
Początek roku obrachunkowego: |
01.09 |
Last Distribution: |
- |
Bank depozytariusz: |
The Bank of New York Mellon SA/NV, Zweigniederlassung Luxemburg |
Kraj pochodzenia funduszu: |
Luxemburg |
Zezwolenie na dystrybucję: |
Austria, Niemcy, Szwajcaria, Wielka Brytania, Luxemburg |
Zarządzający funduszem: |
Erin Xie, Xiang Liu |
Aktywa: |
14,24 mld
USD
|
Data startu: |
06.04.2001 |
Koncentracja inwestycyjna: |
- |
Warunki
Opłata za nabycie: |
3,00% |
Max. Administration Fee: |
1,50% |
Minimalna inwestycja: |
5 000,00 EUR |
Opłaty depozytowe: |
0,45% |
Opłata za odkupienie: |
0,00% |
Uproszczony prospekt: |
Ściągnij (Wersja do wydruku) |
Firma inwestycyjna
TFI: |
BlackRock (LU) |
Adres: |
35a Avenue JF Kennedy, 1855, Luxemburg |
Kraj: |
Luxemburg |
Internet: |
www.blackrock.com
|
Aktywa
Akcje |
|
98,62% |
Fundusze inwestycyjne |
|
1,36% |
Inne |
|
0,02% |
Kraje
USA |
|
73,12% |
Dania |
|
7,56% |
Wielka Brytania |
|
4,89% |
Szwajcaria |
|
4,08% |
Francja |
|
3,60% |
Niemcy |
|
1,27% |
Holandia |
|
1,01% |
Australia |
|
1,00% |
Japonia |
|
0,85% |
Irlandia |
|
0,72% |
Belgia |
|
0,33% |
Inne |
|
1,57% |
Branże
Farmacja/biotechnologia |
|
52,56% |
Usługi zdrowotne |
|
20,88% |
Medyczne produkty i instrumenty |
|
19,23% |
Handel hurtowy |
|
5,04% |
Odzież |
|
0,88% |
Inne |
|
1,41% |